Start Midwest LLC

1. Pfizer Inc. $6,174,703 380 payments
2. AbbVie, Inc. $4,391,374 1,760 payments
3. Janssen Research & Development, LLC $2,275,637 196 payments
4. Deciphera Pharmaceuticals Inc. $1,688,343 210 payments
5. Regeneron Pharmaceuticals, Inc. $1,616,262 267 payments
6. Exelixis Inc. $1,239,826 172 payments
7. BioNTech SE $638,038 161 payments
8. Genmab U.S., Inc. $596,018 53 payments
9. MacroGenics, Inc. $299,139 81 payments
10. SK Life Science, Inc. $242,234 16 payments

1. A Phase 11B Study Evaluating the Safety Tolerability Pharmacokinetics Pharmacodynamics and Antitumor Activity of Pf07220060 As A Single Agent and As Part of Combination Therapy in Participants With Advanced Solid Tumors $2,081,105 70 payments
2. Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 $1,553,166 777 payments
3. A Master Protocol for the Multi-Cohort, Phase 1/2 Study of Dcc-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies $1,550,856 87 payments
4. Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 $1,027,669 472 payments
5. A Phase 1B2 Openlabel Multicenter Dose Escalation and Dose Expansion Study to Evaluate the Safety Tolerability Pharmacokinetics Pharmacodynamics and Antitumor Activity of Pf07220060 in Combination With Pf07104091 Plus Endocrine Therapy in Participants With Advanced Solid Tumors $1,010,321 62 payments
6. A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors $922,890 161 payments
7. Phase 12A Dose Escalation Finding and Expansion Study Evaluating Safety Tolerability Pharmacokinetics Pharmacodynamics and Anti Tumor Activity of Pf07104091 As A Single Agent and in Combination Therapy $750,504 33 payments
8. A Phase 1 Openlabel Multicenter Dose Escalation and Dose Expansion Study to Evaluate the Safety Tolerability Pharmacokinetics and Preliminary Evidence of Antitumor Activity of Pf07284892 Arry558 As A Single Agent and in Combination Therapy in Participants With Advanced Solid Tumors $603,355 41 payments
9. A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer $600,973 51 payments
10. A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants with Advanced or Metastatic Colorectal Cancer $534,885 63 payments

1. Professional salary support $125,952 21 payments
2. Overhead $88,434 21 payments
3. Patient care $53,597 21 payments
4. Other $31,156 18 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.